This article refers to:
Timmins GS. Deuterated drugs; updates and obviousness analysis. Expert Opin Ther Pat. 2017 Dec;27(12):1353-1361.
http://doi.org/10.1080/13543776.2017.1378350
When the above article was first published online, there is an error in Table 1. In the Assignee Status column, for “Deuterium enriched pioglitazone [69]” and “Deuterium-enriched prasugrel [70]” were changed from “Final rejection Abandoned 28 April 2016” and “Nonfinal rejection §103 Abandoned 26 October 2015” to “Allowed”.